Document Detail

Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.
MedLine Citation:
PMID:  15834926     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Accelerated radiotherapy combined with carbogen and nicotinamide (ARCON) to overcome tumor hypoxia and cell proliferation achieved high tumor control and survival in Phase II studies of patients with advanced head and neck and bladder carcinomas. Thus, morbidity and treatment outcomes from the latter study were analyzed to evaluate the therapeutic potential of ARCON. METHODS: Acute and late morbidity was assessed in 105 patients with high-grade superficial or muscle-invasive bladder carcinoma who were given accelerated radiotherapy (50-55 grays in 4 weeks) with carbogen alone or with ARCON. Urinary dysfunction was scored based on daytime frequency, nocturia, incontinence, dysuria, hematuria, and urgency. Bowel morbidity was based on stool frequency and consistency, rectal discharge, blood loss, and medication. Endpoints for treatment outcome were overall survival, disease-free survival, and locoregional control. RESULTS: Nearly all patients experienced reduced ability to retain urine beyond 2 hours, although 20-30% had almost normal function at night. Incidence of acute moderate or worse dysuria was 41% with ARCON and 56% with carbogen; 96% and 76% of patients, respectively, had bowel frequencies > or = 3 times per day. By 10-12 weeks from the start of radiotherapy, acute reactions returned to baseline levels. At 3 years, the daytime frequency < or = 2 times per hour was approximately 75% in both arms. Incidence of severe hematuria (< or = 25%) and urinary urgency (< or = 16%) was much lower. No more than 6% of patients had severe bowel morbidity. With most assays, the differences between schedules were not significant either for acute or late morbidity. Local tumor control and survival rates at 3 years were 53% and 43%, respectively, for ARCON, similar to the rates for carbogen alone. CONCLUSIONS: Historical comparisons suggested no overt increase in normal tissue radiosensitivity when adding carbogen and nicotinamide. Although, for some endpoints, the incidence of late sequelae was higher than expected, overall morbidity was no worse than reported by others. The data indicated that ARCON could achieve a therapeutic gain in patients with advanced bladder carcinoma. A Phase III, randomized, multicenter trial is underway currently in the United Kingdom to evaluate these findings.
Peter J Hoskin; Ana M Rojas; Heather Phillips; Michele I Saunders
Related Documents :
23372636 - Correction: survival of vibrio cholerae in nutrient-poor environments is associated wit...
11157016 - Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,...
16600346 - Cutaneous metastases from transitional cell carcinoma of the bladder.
16287446 - Is adjuvant chemotherapy for bladder cancer safer in patients with an ileal conduit tha...
24085766 - Persistence of minimal residual disease in the bone marrow predicts outcome in follicul...
12165976 - New approach to the adoptive immunotherapy of walker-256 carcinosarcoma with activated ...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer     Volume:  103     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-05-24     Completed Date:  2005-07-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2287-97     Citation Subset:  AIM; IM    
Cancer Research-UK Tumor Biology and Radiation Research Group, Marie Curie Research Wing, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Carbon Dioxide / therapeutic use*
Carcinoma, Squamous Cell / drug therapy,  mortality,  radiotherapy,  therapy*
Carcinoma, Transitional Cell / drug therapy,  mortality,  radiotherapy,  therapy
Cell Hypoxia
Combined Modality Therapy
Disease-Free Survival
Middle Aged
Niacinamide / therapeutic use*
Oxygen / therapeutic use*
Radiotherapy, High-Energy
Survival Rate
Urinary Bladder Neoplasms / drug therapy,  mortality*,  radiotherapy,  therapy*
Reg. No./Substance:
124-38-9/Carbon Dioxide; 7782-44-7/Oxygen; 8063-77-2/carbogen; 98-92-0/Niacinamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas.
Next Document:  Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepa...